Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 10/20 | 1.00 |
| ▸ | HPGD | P15428 | 9/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 6/20 | 0.73 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30991585 | 1.00 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL13669867 | 0.90 | KDM4E (0.85) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL17938790 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| 2'-Methoxyformonetin SCHEMBL29777010 | 0.86 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| 2'-Methoxyformonetin SCHEMBL234355 | 0.86 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL11068551 | 0.85 | KDM4E (0.74) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| Koparin SCHEMBL5723673 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| Koparin SCHEMBL29477154 | 0.84 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL13169526 | 0.83 | KDM4E (0.70) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL12729876 | 0.83 | KDM4E (1.00) | KDM4EALDH1A1HSD17B10HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | claimed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | claimed |
| US-20120003273-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETIES ACT (ACT XXI OF 1860)) (IN) | 2012-01-05 | — | — | US | claimed |
| EP-2346844-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | Council Of Scientific & Industrial Research (IN) | 2011-07-27 | — | — | EP | claimed |
| WO-2010052734-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-14 | — | — | WO | claimed |
| WO-2025137591-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR PROMOTING ZINC SOLUBILIZATION AND ZINC UPTAKE IN PLANTS | Tenfold Technologies, LLC (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2024170772-A1 | EPIGALLOCATECHIN-3-GALLATE (EGCG) ANALOGS FOR USE IN THE TREATMENT OF DISEASES IN WHICH AN INCREASE OF NAD+ IS BENEFICIAL SUCH AS GLAUCOMA | MIM NEUROSCIENCES AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| US-20230003721-A1 | MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS | THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20180042899-A1 | Method of Treating Transplant Rejection and Autoimmune Diseases | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-02-15 | — | — | US | disclosed |
| EP-2346844-B1 | SUBSTITUTED BENZFUROCHROMENES FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL SCIENT IND RES (IN) | 2017-09-20 | — | — | EP | disclosed |
| EP-2346844-B1 | SUBSTITUTED BENZFUROCHROMENES FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL SCIENT IND RES (IN) | 2017-09-20 | — | — | EP | disclosed |
| US-9408826-B2 | Isoflavone anti-viral compounds | Kineta, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| EP-2346844-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | Council Of Scientific & Industrial Research (IN) | 2011-07-27 | — | — | EP | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| WO-2010052734-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052734-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-14 | — | — | WO | disclosed |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-06-04 | — | — | US | disclosed |
| WO-2009026657-A1 | FLAVONOID PPAR AGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | KDM4E 558/4885ALDH1A1 3995/4885HSD17B10 4851/4885 |
| US-20090143279-A1 | Methods and compositions for treating metabolic disorders | PC, PCK2, CS | KDM4E 3739/4885ALDH1A1 860/4885HSD17B10 287/4885 |
| US-20120003273-A1 | SUBSTITUTED BENZFUROCHROMENES AND RELATED COMPOUNDS FOR THE PREVENTION AND TREATMENT OF BONE RELATED DISORDERS | AKR1C3, AKR1C4, SLC10A1 | KDM4E 2194/4885ALDH1A1 1999/4885HSD17B10 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.